Hirota Y., Okamoto M., Baba M., Suhara Y. . Potential of fat-soluble vitamins as a platform for antiviral drug development . Bioorganic and Medicinal Chemistry Letters1272025 · 記述言語： 日本語 掲載種別： 研究論文（学術雑誌） 出版者・発行元： Bioorganic and Medicinal Chemistry Letters Fat-soluble vitamins, including vitamins A, D, E, and K, exhibit antioxidative, anti-inflammatory, and immunomodulatory effects, making them promising candidates for antiviral drug development. This review highlights their structural features, biological roles, and antiviral potential. Vitamin A derivatives modulate immunity and inhibit viral replication, including SARS-CoV-2. Vitamin D analogs enhance immune responses and target viral enzymes, while vitamin E derivatives reduce oxidative stress and may directly inhibit viral replication. Emerging research on vitamin K derivatives suggests potential antiviral applications. These findings underscore the potential of fat-soluble vitamins as innovative antiviral agents, warranting further investigation to optimize efficacy and clinical use. DOI： 10.1016/j.bmcl.2025.130292 Scopus PubMed
Samunuri R., Toyama M., Kasula M., Jha A.K., Okamoto M., Baba M., Sharon A. . Synthesis, Cytotoxicity, and Mechanistic Evaluation of 7-Deazapurine-Based Neplanocin Analogues as Selective Anti-2025 · 記述言語： 日本語 出版者・発行元： Chemistryselect Nucleobase modifications offer a promising route for the discovery of novel antiviral compounds. The synthetic entry of 7H-pyrrolo[2,3-d]pyrimidine with alterations at the 4-position has been thoroughly investigated in the search for bioactive Neplanocin analogs. A key intermediate (4) was synthesized and explored to yield a series of modified carbo-nucleosides (3a–i). Modified 7-deazapurine has been installed to get the targeted 7-deaza carbocyclic nucleosides with an alkyl or aryl. This was accomplished by Pd-cross-coupling reactions with alkyl or aryl organometallics/aryl boronic acids on 7-deazapurines, followed by Mitsunobu coupling and deprotection to produce the final molecules (3a–i). In HBV replication, the anti-HBV activity of 3a–i was evaluated in HepG2.2.15.7 cells. Compounds 3a, 3c, 3d, 3f, 3 g, and 3i showed promise as lead compounds by exhibiting micromolar-level activity on the HBV replicon. The tested compounds demonstrated a dose-dependent inhibition of HBV replication, as demonstrated by the reduced secretion of HBsAg in HepG2.2.15.7 cells, in contrast to the currently approved nucleoside analogue, entecavir (ETV). These findings suggest that the mechanism of action of these analogues is distinct and likely resembles that of previously reported neplanocin derivatives (I & II), which promote the degradation of pregenomic RNA (pgRNA) via a novel pathway. Importantly, S-adenosylhomocysteine hydrolase (SAHase) does not appear to be involved in their antiviral activity, highlighting a unique mechanism for these neplanocin analogues in suppressing HBV replication. DOI： 10.1002/slct.202500784 Scopus
